The global liquid embolic agent market size was estimated at USD 257.9 million in 2024 and is projected to reach USD 595.0 million by 2033, growing at a CAGR of 9.89% from 2025 to 2033. The liquid embolic agent industry is primarily driven by advancements in minimally invasive procedures and the increasing prevalence of vascular diseases worldwide.
As healthcare systems shift towards less invasive techniques, the demand for embolization agents used in treating conditions like aneurysms, arteriovenous malformations (AVMs), and tumors has surged. The growing neurovascular and peripheral vascular abnormalities and diseases such as AVMs, dural arteriovenous fistulas (DAVFs), and hypervascular tumors, among others are primarily driving the market growth. According to a research article published by the National Center for Biotechnology Information, arteriovenous malformations (AVMs) are often asymptomatic in about 15% of cases until a clinical event occurs. Between 41% and 79% of AVMs are present with intracranial hemorrhage. They are the second most common cause of intracranial bleeding after cerebral aneurysms, accounting for approximately 10% of all subarachnoid hemorrhages.
Children are more likely than adults to be present with hemorrhage. While hemorrhages are typically intraparenchymal, they can also primarily occur in the subarachnoid space. In addition, according to an article published by Radiopaedia.org in November 2024, the incidence of solitary AVM is 98% and multiple AVM is 2%. Thus, growing AVM cases are a primary contributor to market growth.
Furthermore, according to an American Chemical Society report published in April 2021, brain aneurysms are abnormal dilations that primarily develop at the branch points of cerebral blood vessels. Over 60% of aneurysms are now managed using minimally invasive endovascular techniques, such as flow diversion or the permanent placement of metallic intrasaccular coils. However, these current devices have an unfavorable primary success rate in approximately 20-30% of cases, and the overall effectiveness varies significantly depending on the aneurysm’s type and location. Hence, this brings a growth opportunity for the liquid embolic agent industry during the forecast period.
Neurovascular embolization is commonly performed using liquid embolic agents to treat conditions such as AVMs, DAVFs, and hypervascular tumors. Currently, commonly used liquid embolic agents include n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) based agents, such as Onyx (Medtronic), Squid (Balt), and PHIL (Terumo), a non-biodegradable iodine-based liquid embolic agent. Additionally, TRUFILL (CERENOVUS, Johnson & Johnson) has recently been introduced. For instance, in March 2024, CERENOVUS, a division of Johnson & Johnson MedTech, announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set. This new offer expands CERENOVUS’s hemorrhagic stroke portfolio by providing a comprehensive procedural set that includes two configuration options and all necessary accessories for preparing and delivering the TRUFILL n-BCA Liquid Embolic System. These agents are favored for their ability to effectively occlude abnormal vascular structures, providing minimally invasive treatment options with high precision. The choice of embolic agent depends on the specific clinical scenario and lesion characteristics, with ongoing innovations aiming to improve safety, handling, and long-term efficacy in neurointerventional procedures.
This product will be delivered within 1-3 business days.
As healthcare systems shift towards less invasive techniques, the demand for embolization agents used in treating conditions like aneurysms, arteriovenous malformations (AVMs), and tumors has surged. The growing neurovascular and peripheral vascular abnormalities and diseases such as AVMs, dural arteriovenous fistulas (DAVFs), and hypervascular tumors, among others are primarily driving the market growth. According to a research article published by the National Center for Biotechnology Information, arteriovenous malformations (AVMs) are often asymptomatic in about 15% of cases until a clinical event occurs. Between 41% and 79% of AVMs are present with intracranial hemorrhage. They are the second most common cause of intracranial bleeding after cerebral aneurysms, accounting for approximately 10% of all subarachnoid hemorrhages.
Children are more likely than adults to be present with hemorrhage. While hemorrhages are typically intraparenchymal, they can also primarily occur in the subarachnoid space. In addition, according to an article published by Radiopaedia.org in November 2024, the incidence of solitary AVM is 98% and multiple AVM is 2%. Thus, growing AVM cases are a primary contributor to market growth.
Furthermore, according to an American Chemical Society report published in April 2021, brain aneurysms are abnormal dilations that primarily develop at the branch points of cerebral blood vessels. Over 60% of aneurysms are now managed using minimally invasive endovascular techniques, such as flow diversion or the permanent placement of metallic intrasaccular coils. However, these current devices have an unfavorable primary success rate in approximately 20-30% of cases, and the overall effectiveness varies significantly depending on the aneurysm’s type and location. Hence, this brings a growth opportunity for the liquid embolic agent industry during the forecast period.
Neurovascular embolization is commonly performed using liquid embolic agents to treat conditions such as AVMs, DAVFs, and hypervascular tumors. Currently, commonly used liquid embolic agents include n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) based agents, such as Onyx (Medtronic), Squid (Balt), and PHIL (Terumo), a non-biodegradable iodine-based liquid embolic agent. Additionally, TRUFILL (CERENOVUS, Johnson & Johnson) has recently been introduced. For instance, in March 2024, CERENOVUS, a division of Johnson & Johnson MedTech, announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set. This new offer expands CERENOVUS’s hemorrhagic stroke portfolio by providing a comprehensive procedural set that includes two configuration options and all necessary accessories for preparing and delivering the TRUFILL n-BCA Liquid Embolic System. These agents are favored for their ability to effectively occlude abnormal vascular structures, providing minimally invasive treatment options with high precision. The choice of embolic agent depends on the specific clinical scenario and lesion characteristics, with ongoing innovations aiming to improve safety, handling, and long-term efficacy in neurointerventional procedures.
Global Liquid Embolic Agent Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global liquid embolic agent market report based on product type, application, end use, and region:Product Type Outlook (Revenue, USD Million, 2021 - 2033)
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- Cyanoacrylates
- N-BCA (n-Butyl Cyanoacrylate)
- N-HCA (n-Hexyl Cyanoacrylate)
- Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Arteriovenous Malformations (AVM)
- Hypervascular Tumors
- Peripheral Vasculature Hemorrhage
- Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Liquid Embolic Agent Market Variables, Trends, & Scope
Chapter 4. Liquid Embolic Agent Market: Product Type Estimates & Trend Analysis
Chapter 5. Liquid Embolic Agent Market: Application Estimates & Trend Analysis
Chapter 6. Liquid Embolic Agent Market: End Use Estimates & Trend Analysis
Chapter 7. Liquid Embolic Agent Market: Regional Estimates & Trend Analysis By Product Type, By Application, By End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Medtronic
- Johnson & Johnson
- B. Braun SE
- Terumo
- Boston Scientific Corporation
- Meril
- Gem srl
- Balt
- Sirtex (BlackSwan Vascular, Inc.)
- INVAMED
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 300 |
| Published | July 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 257.9 Million |
| Forecasted Market Value ( USD | $ 595 Million |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
